S5 Table. Adjusted outcome results – ATS/ERS exacerbations by treatment group: fine vs. extra-fine particle in matched patients.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ATS/ERS exacerbations in outcome period | By treatment group | | Total | P-valuea |
| **Fine-particle** | **Extra-fine particle** |
| 0, n (%) | 5112 (77.0) | 5319 (80.2) | 10431 (78.6) | <0.001 |
| 1, n (%) | 966 (14.6) | 861 (13.0) | 1827 (13.8) |
| 2+, n (%) | 558 (8.4) | 456 (6.9) | 1014 (7.6) |
| Total, n (%) | 6636 (100) | 6636 (100) | 13272 (100) |
| Rate ratio adjusted for baseline confoundersb | 1.00 | 0.90 (0.84, 0.97) |  | |

ATS: American Thoracic Society; ERS: European Respiratory Society.

aConditional logistic regression.

bAdjusted for rhinitis diagnosis and/or therapy (Y/N), COPD diagnosis (ever) (Y/N) and number of prescriptions for SABA (categorised).